Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : JMED - Jones Pharma (specialty pharmaceutical mfr) -- Ignore unavailable to you. Want to Upgrade?

To: babette spatz who wrote (217)	5/14/1999 8:28:00 AM
From: wbASSETt	Read Replies (1) \| Respond to of 268

I wish i had purchased CISCO, you lucky dog !! My neighbor bought CMGI last year and has been doing the "happy dance" ever since. She'll be building a house in the islands soon. I'm glad that I've been accumulating GE, so my retirement is taken care of. JMED it was supposed to be a long term, med. risk to help balance the portfolio. It's done that. If your holding JMED waiting for $60.....it's 2 years out...buy something else! If you want to get into a CISCO / CMGI type stock early, take a look at MSGI (E-Commerce - marketing 25% GE ownership with another 15% by CMGI) wbASSETt

To: babette spatz who wrote (217)	7/15/1999 9:25:00 AM
From: wbASSETt	Respond to of 268

babette JMED Announces Three for Two Stock Split ST. LOUIS--(BUSINESS WIRE)--July 14, 1999--Jones Pharma Inc. (Nasdaq:JMED) announced that the company's board of directors declared a three for two stock split, in the form of a 50 percent stock dividend, to shareholders of record July 26, 1999, to be distributed Aug. 6, 1999. The board further increased the next quarterly cash dividend 7 percent, to .025 per share, to shareholders of record Sept. 15, 1999, payable Oct. 1, 1999. This follows a 17 percent dividend increase announced June 1, 1999, for a combined increase in dividend in 1999 of 24 percent. Jones Pharma Inc., founded in 1981, is an emerging specialty pharmaceutical manufacturer and marketer with an uninterrupted 17-year history of record sales and profits. The company's strategy has been to build a portfolio of growing products through the acquisition of under-promoted, promotion sensitive FDA approved products from other pharmaceutical companies. For further information, please contact Investor Relations: 314/576-6100. -------------------------------------------------------------------------------- Contact: Jones Pharma Inc., St. Louis Lynn Horwitz, 314/576-6100 (www.jmedpharma.com)